Convergence Investment Partners LLC Buys New Shares in Jazz Pharmaceuticals PLC $JAZZ

Convergence Investment Partners LLC bought a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the 4th quarter, HoldingsChannel.com reports. The fund bought 11,380 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,935,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Cardinal Capital Management grew its holdings in shares of Jazz Pharmaceuticals by 0.5% during the 4th quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock valued at $2,471,000 after purchasing an additional 66 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Jazz Pharmaceuticals by 9.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock valued at $130,000 after purchasing an additional 81 shares during the last quarter. Pinnacle Associates Ltd. grew its holdings in shares of Jazz Pharmaceuticals by 0.7% during the 4th quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock valued at $1,905,000 after purchasing an additional 83 shares during the last quarter. Fairbanks Capital Management Inc. grew its holdings in shares of Jazz Pharmaceuticals by 0.4% during the 3rd quarter. Fairbanks Capital Management Inc. now owns 25,023 shares of the specialty pharmaceutical company’s stock valued at $3,298,000 after purchasing an additional 94 shares during the last quarter. Finally, Danske Bank A S grew its holdings in shares of Jazz Pharmaceuticals by 33.3% during the 4th quarter. Danske Bank A S now owns 400 shares of the specialty pharmaceutical company’s stock valued at $68,000 after purchasing an additional 100 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Insider Transactions at Jazz Pharmaceuticals

In other news, Director Norbert G. Riedel sold 3,415 shares of the firm’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $192.00, for a total value of $655,680.00. Following the completion of the sale, the director directly owned 7,024 shares of the company’s stock, valued at approximately $1,348,608. This trade represents a 32.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Mary Elizabeth Henderson sold 5,343 shares of the firm’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $194.49, for a total transaction of $1,039,160.07. Following the completion of the sale, the senior vice president directly owned 28,728 shares of the company’s stock, valued at approximately $5,587,308.72. This represents a 15.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 74,015 shares of company stock worth $14,180,486. 4.30% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $228.77 on Friday. The firm has a market cap of $14.35 billion, a PE ratio of -11,432.78, a price-to-earnings-growth ratio of 0.41 and a beta of 0.27. Jazz Pharmaceuticals PLC has a 12-month low of $105.00 and a 12-month high of $235.00. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. The company’s fifty day simple moving average is $197.18 and its two-hundred day simple moving average is $176.51.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The firm had revenue of $1.07 billion during the quarter. As a group, equities analysts expect that Jazz Pharmaceuticals PLC will post 20.75 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on JAZZ. Royal Bank Of Canada raised their price target on shares of Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Raymond James Financial reissued an “outperform” rating and issued a $239.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Morgan Stanley reissued an “overweight” rating and issued a $245.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, May 7th. Leerink Partners raised their price target on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an “outperform” rating in a report on Wednesday, April 22nd. Finally, Barclays raised their price target on shares of Jazz Pharmaceuticals from $225.00 to $234.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $230.56.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.